Anthracycline analogs The past, present, and future Raymond B. WeissGisele SarosyBrian Leyland-Jones Review Pages: 185 - 197
Enhancement of etoposide-induced cytotoxicity by cyclosporin A Rainhardt OsiekaSiegfried SeeberCarl Gottfried Schmidt Original Articles Pages: 198 - 202
Methotrexate pharmacokinetics in age-fractionated erythrocytes Henrik Schrøder Original Articles Pages: 203 - 207
The effect of buthionine sulphoximine, cimetidine and phenobarbitone on the disposition of amsacrine in the rabbit J. W. PaxtonS. E. FooteR. M. Singh Original Articles Pages: 208 - 212
Effect of Fluosol-DA/O2 on the antitumor activity and pulmonary toxicity of bleomycin Beverly A. TeicherJohn S. LazoChristopher M. Rose Original Articles Pages: 213 - 218
The effects of cimetidine upon the plasma pharmacokinetics of doxorubicin in rabbits Dean E. BrennerJerry C. CollinsKenneth R. Hande Original Articles Pages: 219 - 222
Comparison of 5-FU versus FUDR activity in human colorectal cancer using an in vitro clonogenic assay (HTCA) Michael FlentjeDagmar FlentjePeter Schlag Original Articles Pages: 223 - 225
Pharmacokinetics and metabolism of hexamethylmelamine in mice after IP administration J. DuboisG. AtassiF. Abikhalil Original Articles Pages: 226 - 230
Effects of 5,8-dideazaisopteroylglutamate (IAHQ) on L1210 leukemia in mice when given alone and in combination with methotrexate, probenecid, or verapamil John B. HynesAlayne B. SmithGlen R. Gale Original Articles Pages: 231 - 234
Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group Michael W. DeGregorioBert L. LumBranimir I. Sikic Original Articles Pages: 235 - 238
The effect of verapamil on the pharmacokinetics of adriamycin D. J. KerrJ. GrahamS. B. Kaye Original Articles Pages: 239 - 242
Clinical pharmacology of the biological response modifier maleic anhydride divinyl ether copolymer (MVE-2) Michael G. RosenblumAdan M. RiosEvan M. Hersh Original Articles Pages: 243 - 246
Pharmacokinetics and tissue disposition of the biological response modifier BAY i 7433 (copovithane) in patients with cancer Michael G. RosenblumGabriel N. Hortobagyi Original Articles Pages: 247 - 251
Phase I/II tolerability/pharmacokinetic study with one-hour intravenous infusion of doxifluiridine (5′-dFUrd) 3 g/m2 VS 5 g/m2 QD x 5 per month Sophie D. FossåAsbjørn FlokkmannSheila Linder-Ciccolunghi Original Articles Pages: 252 - 256
Limited efficacy of a four-day course of high-dose cytosine arabinoside in the treatment of poor-risk patients with acute nonlymphocytic leukemia Harvey D. PreislerAzra RazaPeter D'Arrigo Original Articles Pages: 257 - 260
Bioavailability of ifosfamide in patients with bronchial carcinoma T. CernyJ. M. MargisonP. M. Wilkinson Original Articles Pages: 261 - 264
Phase I/II trial of intravesical methotrexate for superficial bladder tumors Cora N. SternbergAlan YagodaE. Darracott Vaughan Jr. Original Articles Pages: 265 - 269
Effect of oral high-dose progestins on the disposition of antipyrine, digitoxin, and warfarin in patients with advanced breast cancer Steinar LundgrenStener KvinnslandMagne Per Ueland Original Articles Pages: 270 - 275
Urinary β2-microglobulin early indicator of high dose cisdiamminedichloroplatinum nephrotoxicity? Influence of furosemide Catherine de GislainMonique DumasJacques Guerrin Original Articles Pages: 276 - 279
A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix R. E. ColemanP. G. HarperE. Wiltshaw Original Articles Pages: 280 - 283
Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma Edward K. MbiddeStephen J. HarlandIan E. Smith Original Articles Pages: 284 - 285
A phase II study of the platinum analogues JM8 and JM9 in malignant pleural mesothelioma Brian M. J. CantwellC. R. FranksAdrian L. Harris Short Communication Pages: 286 - 288
Myocardial contractility and heart pharmacokinetics of adriamycin following a single administration in rat E. MontiF. PiccininiL. Favalli Short Communication Pages: 289 - 291
